Search Results - "BRUGAROLAS, ANTONIO"

RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer by Manzano, Ramon Gonzalez, Catalan-Latorre, Ana, Brugarolas, Antonio

“…Muscle invasive urothelial bladder carcinoma (MIBC) present RB1 and TP53 somatic alterations in a variable percentage of tumors throughout all molecular…”
Get full text

Psycho-Oncological Intervention Through Counseling in Patients With Differentiated Thyroid Cancer in Treatment With Radioiodine (COUNTHY, NCT05054634): A Non-randomized Controlled Study by Javaloyes, Nuria, Crespo, Aurora, Redal, M Carmen, Brugarolas, Antonio, Botella, Lara, Escudero-Ortiz, Vanesa, Sureda, Manuel

“…Diagnosis and treatment of differentiated thyroid carcinomas (DTC) cause anxiety and depression. Additionally, these patients suffer hormonal alterations that…”
Get full text

Relevance of Fc Gamma Receptor Polymorphisms in Cancer Therapy With Monoclonal Antibodies by Mata-Molanes, Juan J., Rebollo-Liceaga, Joseba, Martínez-Navarro, Elena Mª, Manzano, Ramón González, Brugarolas, Antonio, Juan, Manel, Sureda, Manuel

“…Therapeutic monoclonal antibodies (mAbs), including immune checkpoint inhibitors (ICIs), are an important breakthrough for the treatment of cancer and have…”
Get full text

Polymorphisms of the Repeated Sequences in the Enhancer Region of the Thymidylate Synthase Gene Promoter May Predict Downstaging After Preoperative Chemoradiation in Rectal Cancer by VILLAFRANCA, Elena, OKRUZHNOV, Yury, ANGELETTI, Silvia, BRUGAROLAS, Antonio, DOMINGUEZ, Miguel A, GARCIA-FONCILLAS, Jesus, AZINOVIC, Ignacio, MARTINEZ, Enrique, ILLARRAMENDI, Jose J, ARIAS, Fernando, MARTINEZ MONGE, Rafael, SALGADO, Esteban

“…Thymidylate synthase (TS) is an important target enzyme for the fluoropyrimidines. TS gene promoter possesses regulatory tandemly repeated (TR) sequences that…”
Get full text

A novel genomic signature predicting FDG uptake in diverse metastatic tumors by Crespo-Jara, Aurora, Redal-Peña, Maria Carmen, Martinez-Navarro, Elena Maria, Sureda, Manuel, Fernandez-Morejon, Francisco Jose, Garcia-Cases, Francisco J., Manzano, Ramon Gonzalez, Brugarolas, Antonio

“…Background Building a universal genomic signature predicting the intensity of FDG uptake in diverse metastatic tumors may allow us to understand better the…”
Get full text

Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study by Catalán-Latorre, Ana, Sureda, Manuel, Brugarolas-Masllorens, Antonio, Escudero-Ortiz, Vanesa

“…We describe a clinical case of an 84-year-old man diagnosed with non-small cell lung carcinoma and epidermal growth factor receptor mutation, who was treated…”
Get full text

A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs by Crespo-Jara, Aurora, González Manzano, Ramón, Lopera Sierra, Maribel, Redal Peña, María Carmen, Brugarolas Masllorens, Antonio

“…ABSTRACTWe present a sarcoma patient with a tumor reduction of more than 50% in lung metastasis after 2 single courses of the investigational medical product…”
Get full text

Front-line paclitaxel/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer by Cortes, Javier, Rodriguez, Javier, Aramendia, Jose Manuel, Salgado, Esteban, Gurpide, Alfonso, Garcia-Foncillas, Jesus, Aristu, Jose Javier, Claver, Angela, Bosch, Ana, Lopez-Picazo, Jose Maria, Martin-Algarra, Salvador, Brugarolas, Antonio, Calvo, Emiliano

“…Paclitaxel-cisplatin is considered to be a standard therapy for metastatic non-small-cell lung cancer (NSCLC). The aim of this study was to evaluate the…”
Get more information

Colorectal Carcinomas and PTEN/MMAC1 Gene Mutations by DICUONZO, Giordano, ANGELETTI, Silvia, GARCIA-FONCILLAS, Jesus, BRUGAROLAS, Antonio, OKROUZHNOV, Yuri, SANTINI, Daniele, TONINI, Giuseppe, LORINO, Giulia, DE CESARIS, Marina, BALDI, Alfonso

“…Purpose: PTEN/MMAC1/TEP1 is a tumor suppressor gene encoding a dual-specificity protein phosphatase with homology to the cytoskeleton proteins, chicken tensin…”
Get full text

Cytoreductive surgery and perioperative intraperitoneal chemotherapy in patients with peritoneal carcinomatosis of colonic origin: outcomes after 7 years’ experience of a new centre for peritoneal surface malignancies by Bretcha-Boix, Pedro, Farré-Alegre, Jose, Sureda, Manuel, Dussan, Carlos, Pérez Ruixo, Juan José, Masllorens, Antonio Brugarolas

“…Introduction Peritoneal carcinomatosis is a relatively frequent situation in the natural history of colorectal cancer and is associated with a dismal…”
Get full text

Immunological profile could be responsible of the unusual long-lasting cutaneous-only breast cancer recurrence: An observational study by Rebollo, Joseba, González-Manzano, Ramón, Sureda, Manuel, Martínez, Elena Ma, Monedero, Elena, Bretcha, Pedro, Brugarolas, Antonio

“…e13000 Background: A small number of breast cancer patients develops long-lasting loco-regional cutaneous recurrent disease with a delayed appearance of…”
Get full text

Therapeutic drug monitoring (TDM) of tyrosine kinase inhibitors (TKI) in routine practice in an oncology service. preliminary results by Sureda, Manuel, Dominguez, Vanessa, Escudero, Vanesa, Brugarolas, Antonio

“…Abstract only…”
Get full text

FEASIBILITY OF REPEAT SENTINEL NODE BIOPSY (r-SNB) IN IPSILATERAL RELAPSED BREAST CANCER AFTER MASTECTOMY AND SNB: CASE REPORT AND LITERATURE REVIEW by Yáñez, Alejandro Paz, Diaz, Rodolfo Martín, Muñoz, Paula Muñoz, Ortega Ramírez, Jose Rolando, Boix, Pedro Bretcha, Masllorens, Antonio Brugarolas

Get full text

Therapeutic Drug Monitoring of Erlotinib in Non-Small Cell Lung Carcinoma: A Case Study by Ana, Catalán-Latorre, Manuel, Sureda, Antonio, Brugarolas-Masllorens, Vanesa, Escudero-Ortiz

Get full text

Therapeutic drug monitoring of nivolumab in clinical practice: Preliminary experience by Sureda, Manuel, Catalán-Latorre, Ana, Mata, Juan José, Escudero, Vanesa, Brugarolas, Antonio

“…Abstract only e14089 Background: Fixed dose schemes, regardless of body weight, have been accepted by the regulatory agencies for the PD-1 targeting…”
Get full text

Transcriptome (RNA next generation sequencing) for personalizing of cancer treatment: A correlation with previous clinical resistance by Sureda, Manuel, Rebollo, Joseba, González-Manzano, Ramón, Martínez, Elena Ma, Rostagno, Roman, Mata, Juan José, Monedero, Elena, Ortega, Jose, Brugarolas, Antonio

“…Abstract only e15046 Background: RNA Next Generation Sequencing (transcriptome) is a potential useful tool to predict chemoresistance to available anticancer…”
Get full text

DNA and RNA next generation sequencing for personalizing cancer treatment: A single-center experience by Rebollo, Joseba, Sureda, Manuel, González-Manzano, Ramón, Martínez, Elena Ma, Rostagno, Roman, Mata, Juan José, Monedero, Elena, Ortega, Jose, Brugarolas, Antonio

“…Abstract only e13509 Background: Personalized multidrug therapies improve outcomes in patients with drug resistant cancer. For 8 years we have been using…”
Get full text

Contribution of microarrays of gene expression (MAGE) to the definition of PET/CT as a qualified biomarker of early response in metastatic patients by Sureda, Manuel, Crespo-Jara, Aurora, Gonzalez Manzano, Ramon, Redal, Maria del Carmen, Garcia-Cases, Francisco Javier, Martinez Navarro, Elena Mª, Brugarolas, Antonio

“…Abstract only 11573 Background: Proliferating cancer cells consume elevated quantity of glucose, converted into lactate regardless the presence of oxygen…”
Get full text

Abstract 4648: Development and validation of an HPLC-UV method for Sirolimus (sir) quantification in human blood and application to cancer patients in routine clinical practice by Escudero-Ortiz, Vanesa, Valenzuela, Belen, Rebollo, Joseba, Sureda, Manuel, Brugarolas, Antonio

“…Background and objective: After oral administration, SIR (mTOR inhibitor) is rapid absorbed with a bioavailability around 14%. SIR is distributed mostly into…”
Get full text

Determination of serum levels of interleukin 6 (IL6), vascular endotelial growth factor (VEGF), and soluble receptor of interleukin 2 (srIL2) as a markers of tumor activity: A preliminary study by Sureda, Manuel, Valenzuela, Belen, Vazquez, Begona, Escudero, Vanesa, Martínez, Elena Ma, Rebollo, Joseba, Brugarolas, Antonio

“…Abstract only…”
Get full text